Please assess the completion status of the following clinical trial:

Trial Title: Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Must satisfy A and B and C and D below:~* (A) Women aged \> 55~* (B) Postmenopausal~* (C) Osteoporotic with high risk of fracture~Exclusion Criteria:~* Confirmed serum alkaline phosphatase above upper normal limit with no explanation~* Liver disease (AST or ALT \> 2 x upper normal limit).~* Renal disease (serum creatinine \> 2.0 mg/dl).~* Hypercalcemia (Ca \>10.5 mg/dL)~* Elevated blood PTH (intact PTH \> 65 pg/ml)~* Serum 25-OH vitamin D \< 20 ng/ml~* HCT \< 32%.~* History of malignancy (except basal cell carcinoma) or radiation therapy.~* Significant cardiopulmonary disease including unstable coronary artery disease, stage D ACC/AHA heart failure or any other condition that the investigator deems may preclude the subject from participating safely or completing the protocol procedures.~* Major psychiatric disease that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures.~* Excessive alcohol use or substance abuse that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures.~* Known congenital or acquired bone disease other than osteoporosis (including osteomalacia, hyperparathyroidism, Paget's disease)~* Current use or use in the past 6 months of oral bisphosphonate~* Current use or use within the past 3 months of estrogens, selective estrogen receptor modulators, or calcitonin.~* Use of oral or parenteral glucocorticoids for more than 14 days within the past 6 months.~* Any current or previous use of strontium or any parenteral bisphosphonate.~* Known sensitivity to mammalian cell-derived drug products.~* Known sensitivity to teriparatide or any of its excipients.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- denosumab ONLY (Type: EXPERIMENTAL): None
- teriparatide (Forteo®) ONLY (Type: EXPERIMENTAL): None
- denosumab and teriparatide (Forteo®) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).